体细胞HLA-I类分子缺失是免疫逃逸的广泛机制并优化TMB作为检查点抑制剂疗效生物标志物
该研究利用83,644例泛癌基因组数据(小部分有ICI治疗结局)分析HLA-I杂合性缺失(LOH)。HLA-I LOH常见(17%),与TMB呈非线性关系,在中间TMB频繁而在>30突变/Mb时下降。在ICI治疗的非鳞NSCLC中,HLA-I LOH是总生存的显著负向预测因子,与TMB联合可改善生存预测。
要点
- HLA-I LOH在泛癌中常见(17%),与TMB呈非线性「金发姑娘」关系。
- HLA-I LOH在ICI治疗的非鳞NSCLC中是总生存的显著负向预测因子。
- HLA-I LOH与TMB联合可更好识别可能从ICI获益的患者。
核心结论
- HLA-I LOH是泛癌中常见的免疫逃逸机制,与TMB呈非线性关系,并且是ICI治疗后结局的显著负向预测因子。
- HLA-I LOH与TMB联合可能更好地识别可能从ICI获益的患者。
研究设计与样本
- 研究利用泛癌基因组数据集,共83,644例患者样本,其中一小部分有免疫检查点抑制剂(ICI)治疗结局。
主要发现
- HLA-I LOH常见,发生率为17%。
- HLA-I LOH与TMB呈非线性关系:在中间TMB时频繁,但在高于30突变/Mb时患病率下降。
- 在ICI治疗的非鳞非小细胞肺癌患者中,HLA-I LOH是总生存的显著负向预测因子。
- 当HLA-I LOH与TMB联合时,生存预测得到改善。
关键数值与推荐
- HLA-I LOH发生率为17%(泛癌基因组数据集83,644例样本)。
- HLA-I LOH患病率在TMB高于30突变/Mb时下降。
临床怎么用
- 在非鳞NSCLC中,HLA-I LOH可作为ICI治疗总生存的负向预测标志物。
- 将HLA-I LOH与TMB联合可能优化ICI获益人群的筛选。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Neoantigen presentation arises as a result of tumor-specific mutations and is a critical component of immune surveillance that can be abrogated by somatic LOH of the human leukocyte antigen class I (HLA-I) locus. To understand the role of HLA-I LOH in oncogenesis and treatment, we utilized a pan-cancer genomic dataset of 83,644 patient samples, a small subset of which had treatment outcomes with immune checkpoint inhibitors (ICI). HLA-I LOH was common (17%) and unexpectedly had a nonlinear relationship with tumor mutational burden (TMB). HLA-I LOH was frequent at intermediate TMB, yet prevalence decreased above 30 mutations/megabase, suggesting highly mutated tumors require alternate immune evasion mechanisms. In ICI-treated patients with nonsquamous non-small cell lung cancer, HLA-I LOH was a significant negative predictor of overall survival. Survival prediction improved when combined with TMB, suggesting TMB with HLA-I LOH may better identify patients likely to benefit from ICIs. SIGNIFICANCE: This work shows the pan-cancer landscape of HLA-I LOH, revealing an unexpected "Goldilocks" relationship between HLA-I LOH and TMB, and demonstrates HLA-I LOH as a significant negative predictor of outcomes after ICI treatment. These data informed a combined predictor of outcomes after ICI and have implications for tumor vaccine development.This article is highlighted in the In This Issue feature, p. 211.
引用
- Montesion M, Murugesan K, Jin DX, et al. Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response. Cancer Discov. 2020. PMID: 33127846. doi:10.1158/2159-8290.CD-20-0672
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。